Frovatriptan
- Generic Name
- Frovatriptan
- Brand Names
- Frova
- Drug Type
- Small Molecule
- Chemical Formula
- C14H17N3O
- CAS Number
- 158747-02-5
- Unique Ingredient Identifier
- H82Q2D5WA7
- Background
Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head.
- Indication
For the acute treatment of migraine attacks with or without aura in adults.
- Associated Conditions
- Migraine With Aura, Migraine Without Aura, Migraine;Menstrual
- Associated Therapies
- -
Frovatriptan as a Transitional Therapy in Medication Overuse Headache
- Conditions
- Interventions
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 55
- Registration Number
- NCT01044251
- Locations
- 🇨🇦
South Health Campus, Calgary, Alberta, Canada
Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine
- Conditions
- Interventions
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2010-02-15
- Lead Sponsor
- Endo Pharmaceuticals
- Target Recruit Count
- 192
- Registration Number
- NCT00904098
Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Clinvest
- Target Recruit Count
- 55
- Registration Number
- NCT00846495
- Locations
- 🇺🇸
Physician Associates LLC, Oviedo, Florida, United States
🇺🇸Clinvest, Springfield, Missouri, United States
A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
- First Posted Date
- 2009-01-13
- Last Posted Date
- 2013-04-18
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 298
- Registration Number
- NCT00821483
Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals
- Conditions
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- Scott and White Hospital & Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00700128
- Locations
- 🇺🇸
Scott & White Memorial Hospital, Temple, Texas, United States
A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine
- Conditions
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Endo Pharmaceuticals
- Target Recruit Count
- 579
- Registration Number
- NCT00644033
- Locations
- 🇺🇸
Endo Pharmaceuticals, Chadds Ford, Pennsylvania, United States
A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2011-05-26
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 74
- Registration Number
- NCT00440232
- Locations
- 🇺🇸
Jefferson Headache Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.